The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of hormone replacement and immunosuppressants, and association with outcome: E1609 study analysis.
 
Ahmad A. Tarhini
Consulting or Advisory Role - Array BioPharma; BioNTech; Bristol-Myers Squibb; Genentech/Roche; HUYA Bioscience International; Immunocore; Incyte; Merck; Newlink Genetics; Novartis; OncoSec; Pfizer/EMD Serono; Sanofi/Regeneron
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); GreenPeptide (Inst); Incyte (Inst); Incyte (Inst); Merck (Inst); Novartis (Inst); Prometheus (Inst); Prometheus (Inst)
 
Sandra J. Lee
Employment - NantWorks (I)
Stock and Other Ownership Interests - NantWorks (I)
Consulting or Advisory Role - Roche/Genentech
 
Ni Kang
No Relationships to Disclose
 
F. Stephen Hodi
Employment - Dana-Farber Cancer Institute
Stock and Other Ownership Interests - Apricity Health; Torque
Consulting or Advisory Role - 7 Hills Pharma; Aduro Biotech; Bayer; Bristol-Myers Squibb; Compass Therapeutics; EMD Serono; Genentech/Roche; Merck Sharp & Dohme; Novartis; Partners Therapeutics; Partners Therapeutics; Pfizer; Pionyr; Rheos Medicines; Sanofi; Surface Oncology; Takeda; Torque; Verastem
Research Funding - bristol-myers squibb (Inst); Genentech/Roche (Inst); Merck Sharp & Dohme (Inst); novartis (Inst)
Patents, Royalties, Other Intellectual Property - Angiopoietin-2 Biomarkers Predictive of Anti-immune checkpoint response (Inst); Compositions and Methods for Identification, Assessment, Prevention, and Treatment of Melanoma using PD-L1 Isoforms; Methods of Using Pembrolizumab and Trebananib (Inst); patent pending as per institutional policy; patent pending royalties received on MICA related disorders application to institution per institutional IP policy
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Novartis
Other Relationship - Bristol-Myers Squibb; Genentech/Roche
 
Uma N. M. Rao
No Relationships to Disclose
 
Gary Irvin Cohen
Stock and Other Ownership Interests - Abbvie; Celgene; Nymox
Honoraria - Amgen
 
Lawrence E. Flaherty
Consulting or Advisory Role - HUYA Bioscience International; Merck/Schering Plough
Travel, Accommodations, Expenses - Merck/Schering Plough
 
Teresa M. Petrella
Honoraria - Abbvie (I); Astellas Pharma (I); Bayer (I); Bristol-Myers Squibb; Genzyme; Incyte; Janssen (I); Merck; Novartis; Sanofi (I)
Consulting or Advisory Role - Abbvie (I); Astellas Pharma (I); Bayer (I); Bristol-Myers Squibb; Genzyme; InCyte; Janssen (I); Merck; Novartis
Research Funding - Novartis Canada Pharmaceuticals Inc; Roche Canada
 
Vernon K. Sondak
Consulting or Advisory Role - Array BioPharma; Bristol-Myers Squibb; Genentech/Roche; Merck/Schering Plough; Novartis; Pfizer; Polynoma; Regeneron; Replimune
 
John M. Kirkwood
Consulting or Advisory Role - Array BioPharma; Bristol-Myers Squibb; Bristol-Myers Squibb (Inst); Checkmate Pharmaceuticals (Inst); Elsevier; Immunocore; Immunocore (Inst); Iovance Biotherapeutics; Merck (Inst); Novartis
Research Funding - Immunocore (Inst); Merck (Inst); Prometheus (Inst)